ARQQ's Piotroski F-Score of 4/9 indicates weak financial health, with significant red flags in profitability and cash flow despite a strong current ratio and low debt. The company exhibits extreme negative operating margins (-6,589%) and ROE (-181.44%), signaling severe operational inefficiency. Although the Graham Number and intrinsic value are unavailable, the stock trades at an astronomical Price/Sales of 402.52, far exceeding sector averages and suggesting extreme overvaluation. The 52-week price drop of 94.3% and persistent negative earnings underscore deep market skepticism. Analysts have only one rating with a $60 target, but the stock remains vastly overpriced relative to fundamentals.